Tag Archive for: acquisition

Biocomposites adds proprietary NanoBone® technology to its portfolio through the acquisition of Artoss GmbH

/in

NanoBone® technology complements Biocomposites’ absorbable bone regeneration products Artoss to benefit from Biocomposites established, global distribution network Keele, UK, 6 June 2023 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for regenerating bone and managing infection in bone and soft tissue, today announces the acquisition of Artoss GmbH (Artoss), […]

Read more

Ariceum Therapeutics Expands Pipeline with Acquisition of Theragnostics Ltd

/in

Acquisition of next generation radiopharmaceutical clinical pipeline to include Auger-based systemic targeted PARP inhibitor radiation therapies Expansion of operations in the US Acquisition of commercial FDA-approved, diagnostic product NEPHROSCANTM in partnership with GE Healthcare and Ga-68 kit technology IP currently licensed to Novartis Theragnostics’ and Ariceum’s leadership teams to join forces creating a specialist team of […]

Read more

Neuraxpharm announces closing of acquisition of established products from Sanofi

/in

Düsseldorf and Barcelona – February 1, 2023 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces the closing of the previously announced acquisition of two established product portfolios for CNS disorders, pain and vascular diseases from Sanofi. Read more…

Read more

Novo Holdings acquires KabaFusion from Pritzker Private Capital. KabaFusion’s clinician-led management team will remain significant investors in the business alongside Novo Holdings

/in

Novo Holdings, a leading healthcare investment firm, announced today its acquisition of KabaFusion (the “Company”), a leading national provider of home infusion therapies, from Pritzker Private Capital (“PPC”), a leader in family direct investing. Terms of the transaction were not disclosed. Read more here.

Read more

Destiny Pharma appoints Dr Yuri Martina as CMO

/in

Destiny Pharma strengthens Executive Management Team with the appointment of Dr Yuri Martina as Chief Medical Officer Brighton, United Kingdom – 3rd May 2022 – Destiny Pharma plc (AIM:DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, today announces the appointment of Dr. Yuri Martina as Chief Medical Officer (CMO). Read more

Read more